(Press-News.org) Study found which abnormal cells talk to each other in harmful ways and perpetuate lung damage
Scientists are already exploring therapeutic strategies based on this study’s discoveries
Treatments also could help patients with other lung-scarring diseases (COPD, COVID-19, etc.)
CHICAGO --- More than 50% of lung-transplant recipients experience a rejection of their new lung within five years of receiving it, yet the reason why this is such a prevalent complication has remained a medical mystery.
Now, a new Northwestern Medicine study has found that, following transplant and in chronic disease states, abnormal cells emerge and “conversations” between them drives the development of lung damage and transplant rejection.
These findings not only help answer why rejection occurs, but they also have spurred immediate exploration of new drugs to treat transplant rejection and other lung-scarring diseases.
“Chronic lung-transplant rejection has been a ‘black box.’ We knew it happened but did not exactly know why,” said corresponding author Dr. Ankit Bharat, professor of thoracic surgery at Northwestern University Feinberg School of Medicine and executive director of the Northwestern Medicine Canning Thoracic Institute. “Our study provides the first comprehensive cellular and molecular roadmap of the disease.”
The study will be published Oct. 22 in JCI Insight.
Leading cause of death after the first year of transplantation
Surgeons perform approximately 3,000 to 3,500 lung transplants each year in the U.S., and more than 69,000 have been performed worldwide to date. Chronic lung allograft dysfunction (CLAD), which encompasses several manifestations of chronic lung rejection, remains the leading cause of death after the first year of transplantation. There currently are no effective treatments for CLAD once it develops, leaving patients with only one option: re-transplantation.
In the new study, after evaluating almost 1.6 million cells, scientists distinguished between abnormal cells from the donor lung versus cells from the recipient’s own immune system. They discovered the donor-derived structural cells and recipient’s immune cells talk to each other in harmful ways that perpetuate lung damage. The findings could lead to new drug targets and provide insights that could help patients with various lung-scarring diseases, not just transplant recipients.
More findings
The scientists discovered a rogue cell type (KRT17 and KRT5 cells) that drives lung scarring across multiple diseases, including idiopathic pulmonary fibrosis, interstitial lung disease, COPD, COVID-19 lung damage and transplant rejection. By integrating data from this array of scarring lung diseases, the scientists created the first comprehensive reference map showing which molecular features are shared across conditions and which are unique to each disease.
“By comparing chronic rejection to other scarring lung diseases, we identified both shared and unique features,” said Bharat, who also is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “This means treatments developed for one condition might help others. The benefits extend far beyond transplant patients.”
The scientists also identified previously unrecognized cell populations in rejected lungs. These include “exhausted” T cells (which participate in immune response) that remain activated but dysfunctional, and “super-activated” macrophages (immune cells that act like the body’s “clean-up crew”) that promote inflammation and scarring.
Lastly, the scientists developed new computational methods to analyze data from multiple studies together, overcoming technical barriers that previously prevented this kind of comprehensive analysis, Bharat said.
New drug targets identified
The scientists pinpointed specific genes and signaling pathways (like PDGF, GDF15 and TWEAK) that drive scarring, which allows them to identify potential targets for new drugs, Bharat said. Some existing medications, such as nintedanib (sold under the brand names Ofev and Vargatef), and pirfenidone (commonly sold under the brand name Esbriet), which are approved for other lung diseases, might be repurposed for transplant rejection, he said.
“The findings have immediate translational potential,” Bharat said. “We’re already exploring therapeutic strategies based on these discoveries.”
Broad impact on pulmonary fibrosis
While addressing CLAD was the main focus of the paper, this research has major implications for understanding and treating all forms of pulmonary fibrosis, Bharat said.
“The molecular pathways and cell types we identified are relevant to conditions affecting hundreds of thousands of patients with various lung-scarring diseases, not just transplant recipients,” Bharat said. “This work essentially provides a ‘Rosetta Stone’ for understanding lung scarring regardless of the initial trigger.”
Other Northwestern study authors include Dr. Yuanqing Yan, Taisuke Kaihou, Emilia Lecuona, Xin Wu, Masahiko Shigemura,Haiying Sun, Chitaru Kurihara, Ruli Gao, Felix L Nunez and G. R. Scott Budinger.
END
Very early on in our universe, when it was a seething hot cauldron of energy, particles made of matter and antimatter bubbled into existence in equal proportions. For example, negatively charged electrons were created in the same numbers as their antimatter siblings, positively charged positrons. When the two particles combined, they canceled each other out.
Billions of years later, our world is dominated by matter. Somehow matter "won out" over antimatter, but scientists still do not know how. Now, two of the largest experiments attempting to find answers—projects that focus on subatomic particles called neutrinos—have joined forces.
In a ...
Three copies of chromosome 21 causes Down syndrome (DS), and roughly half of children born each year in the United States with DS—approximately 2,600—also have congenital heart defects (CHDs).
What is not known is exactly why the genes on too many copies of chromosome 21 wreak such devastating effects.
In a new paper published in the journal Nature, a team of scientists, including first and co-corresponding author Sanjeev S. Ranade, PhD, assistant professor in the Center for Cardiovascular and Muscular Diseases and Center for Data Science and Artificial Intelligence at Sanford Burnham Prebys, identify a nuclear ...
About The Study: In this cohort study of more than 1,900 patients in randomized clinical trials (RCTs) for advanced epithelial ovarian cancer, Black and Asian patients were underrepresented compared with the general population estimates in the U.S., and Black patients had worse survival outcomes compared with white and Asian patients, despite having similar progression-free survival. Equitable enrollment in clinical trials ensures access to cutting-edge treatments and can lead to outcomes comparable to those of white counterparts. Sustained efforts to improve RCT diversity remain essential to long-term equity in cancer care and survival.
Corresponding ...
About The Study: In this large national cohort, all adverse pregnancy outcomes except small for gestational age were associated with increased risk for atrial fibrillation up to 46 years later. Women with adverse pregnancy outcomes need early preventive actions and long-term clinical follow-up for timely detection and treatment of cardiovascular disorders related to the development of atrial fibrillation.
Corresponding Author: To contact the corresponding author, Casey Crump, MD, PhD, email casey.crump@uth.tmc.edu.
To access ...
When harmful bacteria that cause food poisoning, such as E. coli, invade through the digestive tract, gut cells usually fight back by pushing infected cells out of the body to stop the infection from spreading.
In a new study published today in Nature, scientists from Genentech, a member of the Roche Group, in collaboration with researchers from Oregon Health & Science University, discovered that a dangerous strain of E. coli — known for causing bloody diarrhea — can block gut this defense, allowing ...
Findings from a randomised and blinded clinical trial investigating repeated ketamine infusions for treating depression have revealed no extra benefit for ketamine when added onto standard care for people admitted to hospital for depression. The paper is published in the journal JAMA Psychiatry today [Wednesday 22ndOctober 2025].
The KARMA-Dep (2) Trial involved researchers from St Patrick’s Mental Health Services, Trinity College Dublin, and Queens University Belfast, Ireland. It was led by Declan McLoughlin, Research Professor of Psychiatry at Trinity College Dublin and Consultant Psychiatrist at St Patrick’s Mental Health Services.
Depression ...
Ants have evolved an acute sense of smell, which requires each sensory neuron to choose one scent receptor out of hundreds. In a new study published in Nature, researchers at New York University have discovered what ants use to solve this biological puzzle: a self-regulating system in which choosing one gene physically silences all its neighbors.
A high-stakes sense of smell
Ants communicate via pheromones to hunt, detect outsiders, and determine their role within a colony. Without precise control of olfactory receptors, ant society would unravel. When ants cannot smell, “they stop performing their duties, which leads to anarchy,” explained ...
SAN FRANCISCO—October 22, 2025—Nearly half of all babies born with Down syndrome face congenital heart defects, often involving serious malformations that require surgery in the first months of life.
For decades, scientists have known that having an extra copy of chromosome 21—the genetic cause of Down syndrome—was responsible, but they couldn’t pin down which of its hundreds of genes were key for causing the heart problems.
Now, scientists at Gladstone Institutes have an answer. In a study published in Nature, the researchers leveraged stem cell science and ...
The University of California San Diego School of Medicine’s Centers for Integrative Health has received a five-year, $6.2 million grant from the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) to establish the REACH Center for Translational Science on Whole Person Health.
The three principal investigators are Cassandra Vieten, Ph.D., clinical professor in the Department of Family Medicine at UC San Diego School of Medicine, Gene “Rusty” Kallenberg, ...
PORTOLA VALLEY, Calif., October 22, 2025 - Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced its call for applicants from academia and the private sector for the 2026 Emerging Leader Awards (ELA). These annual awards recognize innovative researchers advancing novel approaches in tick-borne disease diagnostics and treatments, while embodying the future of research leadership in this critical field.
In 2026, Bay Area Lyme Foundation will award two $150,000 ELA grants:
Lyme ...
